Bactiguard Holding AB (CHIX:BACTBS) EBIT: kr-5.3 Mil (TTM As of Mar. 2026)


CHIX:BACTBS Bactiguard Holding AB CHIX:BACTBS
48 GF Score
Price kr128.60
GF Value kr264.39
! 3 Warning Signs
View Full Analysis

What is Bactiguard Holding AB EBIT?

Bactiguard Holding AB CHIX:BACTBS 48 EBIT is kr-5.3 Mil as of Mar. 2026. GuruFocus rates CHIX:BACTBS with a GF Score™ of 48/100 and a GF Value™ of kr264.39. The stock has 3 warning signs investors should review.

Bactiguard Holding AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr-6.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-5.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bactiguard Holding AB's annualized ROC % for the quarter that ended in Mar. 2026 was -4.18%. Bactiguard Holding AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -25.36%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bactiguard Holding AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -0.80%.


Bactiguard Holding AB  (CHIX:BACTBs) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bactiguard Holding AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-28.672 * ( 1 - 29.24% )/( (481.877 + 487.866)/ 2 )
=-20.2883072/484.8715
=-4.18 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Bactiguard Holding AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-23.888/( ( (93.345 + max(1.925, 0)) + (90.615 + max(2.512, 0)) )/ 2 )
=-23.888/( ( 95.27 + 93.127 )/ 2 )
=-23.888/94.1985
=-25.36 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(35.757 + 21.882 + 4.526) - (18.925 + 0 + 41.315)
=1.925

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(35.862 + 25.834 + -1.4210854715202E-14) - (14.128 + 0 + 45.056)
=2.512

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bactiguard Holding AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-5.307/662.128
=-0.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bactiguard Holding AB EBIT Related Terms


Bactiguard Holding AB EBIT Historical Data

* Premium members only.

The historical data trend for Bactiguard Holding AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bactiguard Holding AB EBIT Chart

Bactiguard Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -54.88 -51.16 -133.63 -21.90 -5.53

Bactiguard Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.60 -7.29 -6.36 14.31 -5.97

CHIX:BACTBS vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Bactiguard Holding AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bactiguard Holding AB EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bactiguard Holding AB's EV-to-EBIT falls into.


CHIX:BACTBS
48GF Score
Bactiguard Holding AB CHIX:BACTBS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bactiguard Holding AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-5.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-5.3 Mil mean?
Bactiguard Holding AB (CHIX:BACTBS) has a EBIT of kr-5.3 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bactiguard Holding AB.
Is Bactiguard Holding AB's EBIT too high?
Bactiguard Holding AB's current EBIT is kr-5.3 Mil. Overall, Bactiguard Holding AB has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's EBIT compare to ABT and SYK?
Bactiguard Holding AB's EBIT of kr-5.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bactiguard Holding AB. Bactiguard Holding AB's current EBIT is kr-5.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Bactiguard Holding AB (CHIX:BACTBS) has a current EBIT of kr-5.3 Mil. The stock's GF Value™ is kr264.39, compared to a current price of kr128.60 — trading 51.4% below its estimated fair value. The current EBIT is kr-5.3 Mil. Bactiguard Holding AB's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bactiguard Holding AB (CHIX:BACTBS), the current EBIT is kr-5.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?

Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued. The current stock price of kr128.60 is trading 51.4% below its estimated GF Value™ of kr264.39.

Key valuation signals for CHIX:BACTBS:

  • EBIT: kr-5.3 Mil
  • GF Value™: kr264.39 vs. price of kr128.60 (51.4% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bactiguard Holding AB Business Description

Other Exchanges BACTI B:Sweden5JE:Germany
Address Vasagatan 11, Stockholm, SWE, 111 20
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
48GF Score

Get the complete analysis for CHIX:BACTBS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr128.60
Price
kr264.39
GF Value